ClinicalTrials.gg
CompletedNCT03740204REACTUpdated Nov 5, 2026

The Role of Estrogen in the Neurobiology of Eating Disorders

A Phase 2 interventional study of 17-β estradiol transdermal patches and Placebo Patch in Eating Disorders and Hypoestrogenemia, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now CompletedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
14 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital — 1 open to participants now, 2 under way, none of them phase 3. Feeding and Eating Disorders · Massachusetts General Hospital.

Started
2019
the only one that year
Phase 2
4 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital, this one is the only one that started in 2019, is one of 4 in phase 2, and was the 8th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

1 of the 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 14 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This is a randomized, double blind, placebo-controlled study of the effects of transdermal estradiol versus placebo on cognitive flexibility, reward processing, and eating disorder pathology in hypoestrogenemic female adolescents and young adults (ages 14-35 years) with an eating disorder characterized by extreme dietary restriction and/or excessive exercise. Subjects will be randomized 1:1 to 12 weeks of transdermal estradiol with cyclic progesterone or placebo patches and cyclic placebo pills. Study visits include a screening visit to determine eligibility and visits at baseline, 8 weeks, and 12 weeks. Study procedures comprise behavioral, neuroimaging, and endocrine assessments.

03

Conditions studied

  • Eating Disorders
  • Hypoestrogenemia

Keywords

  • Adolescent
  • Amenorrhea
  • Anorexia Nervosa
  • Cognitive Flexibility
  • Dietary Restriction
  • Eating Disorders
  • Estrogen
  • Excessive Exercise
  • Females
  • Hypoestrogenemia
  • Reward
04

Who can participate

Ages eligible
14 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • 14-35 years
  • Bone age ≥13.5 years (applicable only for participants \<16 years)
  • eating disorder characterized by restriction and/or excessive exercise and high drive for thinness
  • Hypoestrogenemia: Oligo-amenorrhea defined as lack of menses for ≥3 months within a 6-month period of oligomenorrhea (cycle length ≥5 weeks) or absence of menses at >15 years if premenarchal or low estradiol levels evaluated by the study physician
  • Low or normal weight defined by a that is \<85th percentile for 14-18 year olds and a body mass index \<25 kg/m2 for adults

Exclusion criteria

Exclusion criteria:

  • Suicidal ideation where outpatient treatment is determined unsafe by study clinician
  • Other causes of oligo-amenorrhea, unless a study clinician determines that missed menstrual periods are more likely a consequence of restrictive eating
  • Medications that contain estrogen ± progesterone within the past 3 months
  • Levonorgestrel-releasing intrauterine device if subject is unable to provide two to three weekly blood samples for estradiol of if estradiol levels are determined to be too high by study doctor
  • Neurological or psychiatric disorders that may impact neural circuitry of interest
  • Lifetime history of seizure disorder or electroconvulsive therapy
  • Pregnancy/breastfeeding
  • Gastrointestinal tract surgery
  • to estrogen use
  • Any other significant illness or condition that the investigator determines could interfere with study participation or safety or put the subject at any unnecessary risk
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    17-β estradiol with cyclic progesterone

    Drug: 17-β estradiol transdermal patches · Drug: Micronized progesterone 200 MG

  • Placebo comparator
    Placebo

    Drug: Placebo Patch · Other: Placebo Pill.

Interventions

  • Drug17-β estradiol transdermal patches

    17-β estradiol transdermal patches (100 mcg 17-β estradiol/day)

  • DrugPlacebo Patch

    Placebo patch

  • DrugProgesteroneStudies of ProgesteroneProgesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)- administered to those randomized to the transdermal estradiol patch for endometrial protection

  • OtherPlacebo Pill.

    Administered to those receiving the placebo patch to maintain blinding

06

What researchers measure

Primary outcomes

  1. Change in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-β estradiol versus placebo

    The Inhibition-Switching component of the D-KEFS CWIT simultaneously assesses verbal inhibition (suppressing the automatic urge to read the text) and cognitive flexibility/set-shifting (alternating rules on demand). Participants name the color of words representing colors printed in dissonant ink colors (e.g., the word "blue" in red ink). However, if words are framed by a box, they will be instructed to read the word instead. Within-condition scores are calculated by extracting two types of data: completion time and error metrics. The raw time is converted into an age-adjusted scaled score based on national normative data (Mean 10, SD 3). Uncorrected and self-corrected errors are tallied; total error counts are converted to a cumulative scaled score (Mean 10, SD 3). Total scaled scores range from 1-19 (0.1-99.9th percentile), with lower scores indicating clinically significant impairment and higher scores indicating superior performance.

    Time frame: Baseline to 8 weeks

  2. Change in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score with 17-β estradiol versus placebo

    The TEPS Consummatory Pleasure scale specifically captures sensory, physical, or immediate emotional gratification. It consists of 8 self-report items out of the 18 total items on the TEPS scale. Participants rate each of the 8 consummatory items using a 6-point Likert scale. To generate the final Consummatory Pleasure score, the raw values of the 8 items are summed and then averaged. The final score ranges between 1.0 and 6.0 range. Higher scores indicate greater capacity for pleasure. Lower scores indicate anhedonic traits.

    Time frame: Baseline to 8 weeks

  3. Change in delay discounting parameter k using the Monetary Choice Questionnaire with 17-β estradiol versus placebo

    In this computerized task/verbal administration of the MCQ, we assess an individual's extent of discounting the value of future rewards with increasing delay to reward receipt. Subjects will make 27 binary choices between smaller immediate and larger delayed monetary rewards of varying value and delay to reward receipt. From their responses, their Delay Discounting Parameter k is Calculated. The parameter k serves as a direct proxy for behavioral impulsivity and delay tolerance. In the standard MCQ-27, the derived k values range from roughly 0.00016 (highly patient; willing to wait months for a marginally larger reward) to 0.25 (highly impulsive; completely unwilling to wait). Raw k values are heavily skewed to the right and violate normal distribution assumptions required for parametric statistics; thus, raw k parameters are normalized using a log-transformation (natural log ln) before running inferential statistics.

    Time frame: Baseline to 8 weeks

  4. Change in Eating Disorder Inventory-3 (EDI-3) Body Dissatisfaction score with 17-β estradiol versus placebo

    The Body Dissatisfaction (BD) consists of 10 self-report items out of the 91 total items on the EDI-3, isolating the perceptual-affective component of body image disturbance. Participants rate each of the 10 items on a 6-point Likert scale. Total raw scores range from 0-36. Higher values indicate more pronounced body dissatisfaction/worse outcome.

    Time frame: Baseline to 12 weeks

  5. Change in EDI-3 Drive for Thinness score with 17-β estradiol versus placebo

    The Drive for Thinness (DT) scale consists of 7 self-report items out of the 91 total items on the EDI-3, isolating the obsessive preoccupation with weight, restrictive dieting, extreme desire to be thinner, and a psychological terror or intense fear of weight gain. Participants rate each of the 7 items on a 6-point Likert scale. Total raw scores range from 0-28. Higher values indicate more pronounced drive for thinness/worse outcome.

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Change in functional magnetic resonance imaging (fMRI) activation of the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) during a task switching paradigm with 17-β estradiol versus placebo

    Time frame: Baseline to 8 weeks

  2. Change in fMRI activation of the ventromedial prefrontal cortex (VMPFC) and ventral striatum in response to reward receipt with 17-β estradiol versus placebo

    Time frame: Baseline to 8 weeks

  3. Change in fMRI activation of the VMPFC and ventral striatum during delay discounting with 17-β estradiol versus placebo

    Time frame: Baseline to 8 weeks

  4. Change in the Eating Disorder Examination (EDE) Dietary Restraint subscale with 17-β estradiol versus placebo

    The Dietary Restraint subscale consists of 5 items of the total 22 items rated on a forced-choice 7-point Likert scale ranging from 0 to 6 (0 = 0 days; 1 = 1-5 days; 2 = 6-12 days; 3 = 13-15 days; 4 = 16-22 days; 5 = 23-27 days; 6 = 28 days), targeting behavioral intentions and explicit attempts to restrict caloric intake over the past 28 days. Total score for the subscale is calculated by taking the average of the 5 constituent item scores. Total scores range from 0-6. Higher values indicate more pronounced dietary restraint/worse outcome.

    Time frame: Baseline to 12 weeks

  5. Change in caloric intake by 4-day food diary with 17-β estradiol versus placebo

    The 4-day food diary (4DFR) captures detailed self-report food intake and includes 3 weekdays and 1 weekend day. Records will be analyzed by dieticians in the Clinical Research Center using NDS-R software v2008 (Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN. The mean caloric intake over 4 days was calculated by summing the caloric intake each day of the 4 days and taking the average.

    Time frame: Baseline to 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Breithaupt L, Slattery M, Lauze M, Petterway F, Lindman L, Cravitz M, Naticchia S, Seenivasa S, Powers M, Javaras KN, Alperovitz DJ, Halperin J, Dechant E, Thomas JJ, Lawson EA, Lee H, Pizzagalli DA, Romer AL, Kumar P, Plessow F, Misra M, Eddy KT. Study protocol for a randomized, placebo-controlled, double-masked mechanistic clinical trial of transdermal estrogen replacement in hypoestrogenic eating disorders to explore the role of estrogen on cognitive flexibility and reward processing. Contemp Clin Trials. 2025 Jul;154:107924. doi: 10.1016/j.cct.2025.107924. Epub 2025 Apr 26. PubMed 40294815 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2019 to primary completion in Dec 2025, 78 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 14, 2018
StartActual
Jun 13, 2019
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025was Dec 2026
Results delay requested
Oct 16, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Study completion
Dec 31, 2026→Dec 30, 2025 (actual)
Nov 5, 2026
Enrollment
120→122
Nov 5, 2026
Interventions
Added Drug: 17-β estradiol transdermal patches·Drug: Placebo Patch·Drug: Micronized progesterone 200 MG·Placebo Pill.; removed Drug: 17-β estradiol transdermal patches with cyclic progesterone·Drug: Placebo patch and pill
Nov 5, 2026
Primary outcomes
3 edited, 2 description edited
What changed in the outcomes
  • EditedChange in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score (Range: 8-48; direction: Higher values indicate more pronounced consummatory pleasure/better outcome) with 17-β estradiol versus placeboTime frame: Baseline to 8 weeks
  • EditedChange in Eating Disorder Inventory-3 (EDI-3) Body Dissatisfaction score (Range: 0-36; direction: Higher values indicate more pronounced body dissatisfaction/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
  • EditedChange in EDI-3 Drive for Thinness score (Range: 0-28; direction: Higher values indicate more pronounced drive for thinness/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
  • DescriptionChange in delay discounting parameter k using the Monetary Choice Questionnaire with 17-β estradiol versus placebo: how it is measured was reworded
  • DescriptionChange in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-β estradiol versus placebo: how it is measured was reworded
Nov 5, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedChange in the Eating Disorder Examination (EDE) Dietary Restraint subscale (Range: 0-6; direction: Higher values indicate more pronounced dietary restraint/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
  • DescriptionChange in caloric intake by 4-day food diary with 17-β estradiol versus placebo: how it is measured was reworded
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    Study completion Dec 31, 2026→Dec 30, 2025 (now actual)
    Enrollment 120→122
    Primary outcomes 3 edited, 2 description edited
    What changed in the outcomes
    • EditedChange in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score (Range: 8-48; direction: Higher values indicate more pronounced consummatory pleasure/better outcome) with 17-β estradiol versus placeboTime frame: Baseline to 8 weeks
    • EditedChange in Eating Disorder Inventory-3 (EDI-3) Body Dissatisfaction score (Range: 0-36; direction: Higher values indicate more pronounced body dissatisfaction/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
    • EditedChange in EDI-3 Drive for Thinness score (Range: 0-28; direction: Higher values indicate more pronounced drive for thinness/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
    • DescriptionChange in delay discounting parameter k using the Monetary Choice Questionnaire with 17-β estradiol versus placebo: how it is measured was reworded
    • DescriptionChange in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-β estradiol versus placebo: how it is measured was reworded
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedChange in the Eating Disorder Examination (EDE) Dietary Restraint subscale (Range: 0-6; direction: Higher values indicate more pronounced dietary restraint/worse outcome) with 17-β estradiol versus placeboTime frame: Baseline to 12 weeks
    • DescriptionChange in caloric intake by 4-day food diary with 17-β estradiol versus placebo: how it is measured was reworded
    Interventions Added Drug: 17-β estradiol transdermal patches·Drug: Placebo Patch·Drug: Micronized progesterone 200 MG·Placebo Pill.; removed Drug: 17-β estradiol transdermal patches with cyclic progesterone·Drug: Placebo patch and pill
    + 5 other changes: identifiers, verification date, registry dates, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03740204
Responsible party
Madhusmita Misra (Division Chief, Pediatric Endocrinology, Massachusetts General Hospital) — Principal investigator
First posted
Nov 14, 2018
Start date
Jun 13, 2019
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Nov 5, 2026

Study contacts

Madhusmita Misra, M.D., M.P.H.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progesterone

Start the discussion